Advertisement

In-hospital and post-discharge outcomes of pediatric acute myocarditis underwent after high-dose steroid or intravenous immunoglobulin therapy

  • Ming-Shyan Lin
  • Yu-Hsiang Tseng
  • Mei-Yen Chen
  • Chang-Min Chung
  • Ming-Horng Tsai
  • Po-Chang Wang
  • Jung-Jung Chang
  • Tien-Hsing Chen
  • Yu-Sheng LinEmail author
Open Access
Research article
  • 128 Downloads
Part of the following topical collections:
  1. Non-coronary artery cardiac disease

Abstract

Background

High-dose steroids and intravenous immunoglobulin (IVIG) are controversial treatments for pediatric patients with acute myocarditis. This study aimed to investigate their efficacies in the Taiwanese pediatric population.

Methods

This study evaluated 5563 acute myocarditis patients from the Taiwan’s National Health Insurance Research Database and identified 1542 pediatric patients hospitalized for acute myocarditis between January 1, 2001 and December 31, 2011. The exclusion criteria were age of > 11 years, associated cardiovascular comorbidities, autoimmune disease, malignancy before the index hospitalization, extracorporeal membrane oxygenation, intra-aortic balloon pumping, and dual therapy using IVIG and high-dose steroids.

Results

After 2:1 propensity score matching, we identified 208 subjects without steroid therapy and 104 subjects who received high-dose steroids. The mean age in that cohort was 2.6 ± 2.9 years, and high-dose steroid therapy had no significant effects on major in-hospital complications and post-discharge outcomes. After 2:1 propensity score matching, we identified 178 subjects without IVIG therapy and 89 subjects who received IVIG. The mean age in that cohort was 2.0 ± 2.1 years, and IVIG had no significant effects on the major outcomes.

Conclusions

The present study revealed that high-dose steroid or IVIG therapy had no significant effects on major in-hospital complications, late heart failure hospitalization, and long-term mortality.

Keywords

Acute myocarditis Immunoglobulin Immunotherapy Immunosuppression Propensity score analysis 

Abbreviations

aOR

Adjust odds ratio

AV block

Atrioventricular block

CPR

Cardiac pulmonary resuscitation

ECMO

Extra-corporeal membrane oxygenation

IABP

Intraaortic balloon pumping

ICD

International classification of diseases

IVIG

Intravenous immunoglobulin

MCS

Mechanical circulation support

NHI

National Health Institute

NHIRD

National Health Insurance Research Database

PSM

Propensity scoring method

VT/VF

Ventricular tachycardia/fibrillation

Background

Acute myocarditis is defined as inflammation of the myocardium that is related to viral infection and autoimmune reactions [1], which may lead to the sudden onset of heart failure, arrhythmia, fulminant hemodynamic collapse, and death. This condition is common in the pediatric population, as approximately 55% of autopsied pediatric patients were diagnosed with myocarditis [2]. Although most children can recover from acute myocarditis after treatment, approximately 9% of patients will progress to dilated cardiomyopathy during mid-term and long-term follow-up. Therefore, it is important to manage the complications of acute myocarditis in this population. The current recommendations for pediatric myocarditis emphasize primary treatment using supportive medical therapy [3], which can involve inotropic agents for acute heart failure and mechanical circulatory support (MCS) for severe cases.

Immunotherapies are occasionally used in cases with residual refractory and chronic cardiac dysfunction. For example, high-dose steroids reportedly have a therapeutic effect in pediatric myocarditis cases [4, 5, 6, 7], and can promote the recovery of left ventricle systolic function in acute myocarditis [8]. However, recent reviews and meta-analyses have indicated that high-dose steroid therapy did not significantly influence clinical outcomes [9] and did not reduce the mortality rate [10, 11]. Nevertheless, despite the controversial results among pediatric patients with acute myocarditis, high-dose steroids are used in 25–30% of American pediatric myocarditis cases [12]. Intravenous immunoglobulin (IVIG) is another immune-modulating therapy that may be used for pediatric acute myocarditis based on its anti-viral and anti-inflammatory effects [13]. However, a recent study failed to reveal a survival benefit associated with IVIG therapy for pediatric myocarditis [14]. Despite these heterogeneous results, all of the related studies regarding IVIG or high-dose steroid therapy have been limited by their small size and matched-controlled designs. Therefore, the present study aimed to evaluate the effects of high-dose steroid and IVIG therapy on Taiwanese pediatric patients with acute myocarditis using data from a nationally representative cohort.

Material and methods

Data source

This nationally representative population-based retrospective cohort study evaluated data retrieved from the Taiwan’s National Health Insurance Research Database (NHIRD), which is maintained by the Taiwan National Health Research Institute. The NHIRD contains healthcare information for 99.91% of the Taiwanese population who are enrolled in the National Health Insurance (NHI) program (approximately 23.20 million people in 2012). The NHIRD records all medical data, including records for inpatient and outpatient care, and basic data regarding age, sex, underlying diseases, and the treating hospital’s characteristics. The accuracy and validity of the NHIRD data is regularly evaluated by the NHI Bureau [15]. The present study evaluated all patients who were admitted to hospital for treatment of acute myocarditis. The study’s retrospective protocol was approved by the institutional review board of Chang Gung Memorial Hospital (103-6244B) and the need for written informed consent was waived by the ethics committee due to all NHIRD data had been de-identified for research purposes.

Study population and definitions

Between January 1, 2001 and December 31, 2011, 5563 patients were hospitalized for acute myocarditis and were identified using the International Classification of Diseases, Ninth Revision code (422.0), which was validated in a previous study [16]. The exclusion criteria at the index hospitalization were age of > 11 years, diabetes mellitus (250), hypertension (401–405), hyperlipidemia (272.0–272.2), ischemic heart disease (410–414), heart failure (428), cerebrovascular accident (430–438), renal failure (584–586), autoimmune disease (136.1, 443.1, 446.0, 446.2, 446.4, 446.5, 446.7, 555, 556, 694.4, 710.0, 710.1, 710.2, 710.3, 710.4, 714.0), malignancy (140–208), extracorporeal membrane oxygenation, intra-aortic balloon pumping, and a combination of IVIG and high-dose steroid therapy. The remaining patients were grouped according to whether they received no high-dose steroids or IVIG (no immunotherapy), only high-dose steroid treatment (steroids alone), or only IVIG (IVIG alone). High-dose steroid therapy was defined as intravenous prednisolone used at > 10 mg/kg/day according to the patient’s average body weight. The use of IVIG was defined as IVIG treatment during the index hospitalization. The study flow chart is shown in Fig. 1. All clinical comorbidities, complications, and outcomes were identified using the International Classification of Diseases, Ninth Revision codes, and steps for managing acute myocarditis during the admission were recorded as completely as possible. These steps included confirmatory examinations (virus detection, cardiac magnetic resonance imaging, and cardiac biopsy), medication-based treatments (any intravenous inotropic agents, high-dose steroids, and IVIG), use of a temporary pacing device, and resuscitation methods (electrical cardioversion, intubation with ventilation support, and cardiopulmonary resuscitation [CPR]).
Fig. 1

Flow chart of the study design and enrollment. *Comorbidities: Diabetes mellitus, hypertension, hyperlipidemia, ischemic heart disease, heart failure, cerebrovascular accident, renal failure, autoimmune disease, malignancy. *Steroid: High-dose steroid. ECMO:extra-corporeal membrane oxygenation; IVIG:intravenous immunoglobulin; IABP:intraaortic balloon pumping

Study design

Two cohorts were evaluated in this study. The first cohort was used to assess the effects of high-dose steroid therapy on pediatric acute myocarditis, while the second cohort was used to assess the effects of IVIG. To reduce potential confounding and selection biases, because the two groups were not randomized, propensity scoring matching (PSM) was performed [17]. Each patient in the high-dose steroid or IVIG groups was matched to 2 control patients who did not receive high-dose steroids or IVIG (i.e., no immunotherapy) using the probability calculated via logistic regression based on the following confounding variables: sex, age, anti-heart failure medications (ACEi/ARB, beta blocker, digoxin, loop diuretics, and potassium-sparing diuretics), inotropic agents (dobutamine, milrinone, dopamine, norepinephrine), severity assessment (ventricular tachycardia/fibrillation [VT/VF], CPR, bradycardia, cardioversion, temporary pacemaker, and intensive care unit [ICU] admission), and the year of the index hospitalization. The matching procedure was performed using SAS (version 9.3; SAS Institute, Cary, NC).

Outcome assessments

The outcomes of interest were defined as in-hospital complications and discharge outcomes. In-hospital complications were defined as new-onset acute renal failure, new onset dialysis, stroke, and cardiovascular death. Discharge outcomes were defined as any clinical event after the index hospitalization, such as high-grade AV block, VT/VF, use of dialysis, heart failure hospitalization, stroke, heart transplantation, cardiovascular death, and all-cause mortality. Cardiovascular death was defined as death resulting from acute myocardial infarction, sudden cardiac death, heart failure, pulmonary embolism, dysrhythmia unrelated to sudden cardiac death, stroke, and peripheral artery disease. All-cause mortality was defined as death from any cause within 30 days after the index admission date, regardless of whether the patient died during the hospitalization or after discharge.

Statistical analysis

The pre-matching clinical characteristics were compared between the immunotherapy and non-immunotherapy groups using Fisher’s exact test for categorical variables and using one-way analysis of variance for continuous variables. The clinical characteristics were compared between the immunotherapy groups (high-dose steroids and IVIG) and the matched controls using Fisher’s exact test for categorical variables and using the t-test for continuous variables. The in-hospital outcomes were compared between the study groups using multivariable logistic regression analysis. The continuous in-hospital outcomes (i.e., days of ventilator support) were compared between the study groups using multivariable linear regression analysis. Multivariable Cox proportional hazard models were used to compare the times to the first occurrence of the various outcomes between the study groups. All multivariable analyses were adjusted for the subjects’ propensity scores [17]. The PSM was performed based on the nearest-neighbor method (greedy matching) and a caliper radius of 0.5 sigma, which signifies the maximum tolerated distance in the propensity score. All data analyses were performed using IBM SPSS software (version 22; IBM Corp., Armonk, NY).

Results

The present study evaluated 1542 pediatric patients who were hospitalized for acute myocarditis between January 1, 2001 and December 31, 2011. The baseline characteristics are listed in Table 1. Patients who received immunotherapy were younger than the patients who did not receive immunotherapy (high-dose steroids alone: 2.6 ± 2.9 years, IVIG alone: 1.9 ± 2.1 years, no immunotherapy: 2.9 ± 2.6 years).
Table 1

Demographic and clinical data of the study patients before propensity score matching

Variable

Neither steroid nor IVIG

Steroid alone*

IVIG alone

P

Number of patients

1342

105

95

Male gender—no. (%)

713 (53.1)

57 (54.3)

62 (65.3)

0.072

Age (year)

2.9 ± 2.6

2.6 ± 2.9

1.9 ± 2.1

< 0.001

Age group—no. (%)

 

< 0.001

< 1 yrs.

394 (29.4)

44 (41.9)

39 (41.1)

 

1~2 yrs.

432 (32.2)

33 (31.4)

42 (44.2)

 

3~5 yrs.

337 (25.1)

12 (11.4)

7 (7.4)

 

6~11 yrs.

179 (13.3)

16 (15.2)

7 (7.4)

 

Oral Medication—no. (%)

ACEi/ ARB

66 (4.9)

10 (9.5)

5 (5.3)

0.131

Beta blocker

58 (4.3)

6 (5.7)

4 (4.2)

0.723

Digoxin

66 (4.9)

14 (13.3)

6 (6.3)

0.003

Loop diuretics

50 (3.7)

15 (14.3)

6 (6.3)

< 0.001

Potassium-sparing diuretics

9 (0.7)

4 (3.8)

1 (1.1)

0.017

Intravenous agents—no. (%)

Dobutamine

68 (5.1)

32 (30.5)

13 (13.7)

< 0.001

Milrinone

31 (2.3)

7 (6.7)

11 (11.6)

< 0.001

Dopamine

127 (9.5)

40 (38.1)

23 (24.2)

< 0.001

Norepinephrine

4 (0.3)

2 (1.9)

0 (0.0)

0.104

Examination—no. (%)

Cardiac MRI

18 (1.3)

5 (4.8)

9 (9.5)

< 0.001

Cardiac biopsy

1 (0.1)

1 (1.0)

0 (0.0)

0.243

Virus detection

404 (30.1)

53 (50.5)

40 (42.1)

< 0.001

Severity assessment—no. (%)

VT/VF

9 (0.7)

1 (1.0)

1 (1.1)

0.428

CPR

38 (2.8)

12 (11.4)

6 (6.3)

< 0.001

Bradycardia

13 (1.0)

2 (1.9)

1 (1.1)

0.489

Cardioversion

20 (1.5)

6 (5.7)

4 (4.2)

0.005

Temporary Pacemaker

11 (0.8)

2 (1.9)

0 (0.0)

0.375

ICU stay

304 (22.7)

65 (61.9)

28 (29.5)

< 0.001

‡ Fisher’s exact test for categorical variable or one-way ANOVA for continuous variable;

*Steroid alone: those patients received high-dose steroid therapy

Abbreviations: ACEi angiotensin-converting enzyme inhibitor), ARB angiotensin receptor blocker, CPR cardiopulmonary resuscitation, ICU intensive care unit, IVIG intravenous immunoglobulin, MRI magnetic resonance imaging, VT/VF ventricular tachycardia/ventricular fibrillation

Patients who only received high-dose steroids were more likely to receive inotropic agents (dobutamine or dopamine) than patients who received IVIG or no immunotherapy. However, patients who received high-dose steroids were also more likely to be admitted to the ICU than patients who received IVIG (61.9% vs 29.5%). Relative to patients who received no immunotherapy, patients who received immunotherapy had a similar incidence of cardiac arrhythmia (VT, VF, and bradycardia) but were more likely to require resuscitation (cardiac massage and cardioversion) (P < 0.005). Less than 10% of the subjects received standard medications for heart failure (ACEi/ARB, beta blockers, potassium-sparing diuretics), and digoxin plus loop diuretics were common medications. A small number of patients underwent cardiac magnetic resonance imaging and cardiac biopsy.

Effects of high-dose steroids in pediatric patients with acute myocarditis

The PSM process matched 104 patients who received high-dose steroids to 208 patients who received no immunotherapy (Fig. 1). Table 2 shows that there were no significant differences between the groups in terms of their baseline characteristics, age, anti-heart failure medications, inotropic agent use, and severity measures. The mean age was 2.6 ± 3.0 years and > 70% of the patients were toddlers (< 2 years old). Table 3 shows that there were no significant differences in the two groups’ in-hospital complications, including acute renal failure, new onset dialysis, and heart transplantation. Furthermore, there was no significant difference in the in-hospital mortality rates (P = 0.758). Post-discharge VT/VF, high-degree AV block, and renal failure requiring dialysis were rare. There were also no significant differences in the incidences of heart failure hospitalization, cardiovascular death, and all-cause mortality (Fig. 2a, Table 4).
Table 2

Demographic and clinical data of the study patients after propensity score matching

 

First cohort

Second cohort

Variable

Non-Steroid*

Steroid*

P

Non-IVIG

IVIG

P

Number of patients

208

104

178

89

Male gender—no. (%)

108 (51.9)

56 (53.8)

0.810

111 (62.4)

58 (65.2)

0.688

Age (year)

2.4 ± 2.8

2.6 ± 2.9

0.660

1.7 ± 1.9

2.0 ± 2.1

0.313

Age group

  

0.875

  

0.576

< 1 yrs.

87 (41.8)

44 (42.3)

 

79 (44.4)

35 (39.3)

 

1~2 yrs.

67 (32.2)

32 (30.8)

 

80 (44.9)

40 (44.9)

 

3~5 yrs.

28 (13.5)

12 (11.5)

 

8 (4.5)

7 (7.9)

 

6~11 yrs.

26 (12.5)

16 (15.4)

 

11 (6.2)

7 (7.9)

 

Oral Medication—no. (%)

ACEi/ ARB

22 (10.6)

10 (9.6)

0.846

8 (4.5)

5 (5.6)

0.765

Beta blocker

8 (3.8)

6 (5.8)

0.563

7 (3.9)

4 (4.5)

1.000

Digoxin

29 (13.9)

14 (13.5)

1.000

12 (6.7)

5 (5.6)

0.797

Loop diuretics

26 (12.5)

15 (14.4)

0.723

9 (5.1)

6 (6.7)

0.581

Potassium-sparing diuretics

6 (2.9)

4 (3.8)

0.736

2 (1.1)

1 (1.1)

1.000

Intravenous agents—no. (%)

Dobutamine

56 (26.9)

31 (29.8)

0.595

18 (10.1)

10 (11.2)

0.833

Milrinone

13 (6.3)

7 (6.7)

1.000

7 (3.9)

6 (6.7)

0.369

Dopamine

77 (37.0)

39 (37.5)

1.000

29 (16.3)

17 (19.1)

0.607

Norepinephrine

3 (1.4)

2 (1.9)

1.000

0 (0.0)

0 (0.0)

Examination—no. (%)

Cardiac MRI

6 (2.9)

5 (4.8)

0.516

3 (1.7)

7 (7.9)

0.018

Cardiac biopsy

0 (0.0)

1 (1.0)

0.333

0 (0.0)

0 (0.0)

Virus detection

107 (51.4)

52 (50.0)

0.812

54 (30.3)

34 (38.2)

0.215

Severity assessment—no. (%)

VT/VF

5 (2.4)

1 (1.0)

0.668

3 (1.7)

1 (1.1)

1.000

CPR

25 (12.0)

11 (10.6)

0.851

9 (5.1)

5 (5.6)

1.000

Bradycardia

6 (2.9)

2 (1.9)

0.723

1 (0.6)

1 (1.1)

1.000

Cardioversion

16 (7.7)

6 (5.8)

0.643

5 (2.8)

3 (3.4)

1.000

Temporary pacemaker

6 (2.9)

2 (1.9)

0.723

1 (0.6)

0 (0.0)

1.000

ICU stay

130 (62.5)

64 (61.5)

0.902

42 (23.6)

23 (25.8)

0.762

‡ Fisher’s exact test for categorical variable or t-test for continuous variable;

*Steroid: patients received high-dose steroid therapy; non-steroid: patients without receiving high-dose steroid therapy

Abbreviations: ACEi angiotensin-converting-enzyme inhibitor), ARB angiotensin receptor blocker, CPR cardiopulmonary resuscitation, ICU intensive care unit, IVIG intravenous immunoglobulin, MRI magnetic resonance imaging, VT/VF ventricular tachycardia/ventricular fibrillation

Table 3

In hospital outcomes

 

First cohort study

Second cohort study

Variable

Non-Steroid*

Steroid*

P

Non IVIG

IVIG

P

Number of patients

208

104

178

89

Acute renal failure —no. (%)

1 (0.5)

1 (1.0)

0.624

0 (0.0)

0 (0.0)

New onset of dialysis —no. (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Heart transplantation—no. (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

In hospital death—no. (%)

27 (13.0)

13 (12.5)

0.758

10 (5.6)

5 (5.6)

0.758

‡ Adjusted for propensity score (logistic regression for binary outcome or linear regression for continuous outcome);

*Steroid: patients received high-dose steroid therapy; non-steroid: patients without receiving high-dose steroid therapy

Abbreviations: IVIG intravenous immunoglobulin

Fig. 2

Multivariable stratified analyses for the association between immunotherapies and discharge outcomes. (a) Steroid therapy versus non-steroid therapy and (b) IVIG therapy versus non-IVIG. Some variables did not showed here due to hazard ratio cannot be calculated based on no events. *Steroid: High-dose steroid

Table 4

Discharge outcomes for those survived during the index admission

 

First cohort

Second cohort

Variable

Non-Steroid*

Steroid*

P

Non-IVIG

IVIG

P

Number of patients

181

91

168

84

VT/VF—no. (%)

2 (1.1)

0 (0.0)

0 (0.0)

0 (0.0)

High-grade AVB—no. (%)

1 (0.6)

0 (0.0)

0 (0.0)

0 (0.0)

Cardiac arrest—no. (%)

0 (0.0)

1 (1.1)

0 (0.0)

0 (0.0)

Heart failure—no. (%)

14 (7.7)

8 (8.8)

0.891

6 (3.6)

2 (2.4)

0.581

Heart transplantation—no. (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Any dialysis—no. (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

New occurrence of dialysis

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

All-cause mortality

16 (8.8)

9 (9.9)

0.919

8 (4.8)

0 (0.0)

CV death

8 (4.4)

4 (4.4)

0.871

4 (2.4)

0 (0.0)

‡ Adjusted for propensity score (Cox regression);

*Steroid: those patients received high-dose steroid therapy; non-steroid: those patients without receiving high-dose steroid therapy

Abbreviations: AVB atrioventricular block, CV cardiovascular, IVIG intravenous immunoglobulin, VT ventricular tachycardia, VF ventricular fibrillation

Effects of IVIG in pediatric patients with acute myocarditis

The PSM process matched 89 patients who received IVIG alone to 178 patients who received no immunotherapy. The two groups were well balanced in terms of the patients’ clinical characteristics (Table 2). Most patients were male (> 60%) and the mean age was 2.0 ± 2.1 years (> 70% of patients were < 2 years old). The two groups did not include any patients who developed acute renal failure, new onset dialysis, or heart transplantation, and both groups had the same rate of in-hospital mortality (5.6%) (Table 3). The two groups also did not have any patients who developed post-discharge VT/VF, high-grade AV block, and renal failure requiring dialysis, and there was no difference in the incidences of heart failure hospitalization (Fig. 2b). Table 4 shows that the IVIG alone group did not experience any deaths (0/84), although 8 patients in the control group died, including 4 cases (2.4%) of cardiovascular death.

Discussion

This well-matched nationally representative retrospective cohort study revealed that both immunotherapies (high-dose steroids and IVIG) might not affect the real-world rates of in-hospital mortality and post-discharge hospitalization for late heart failure. Nevertheless, despite the neutral effect of high-dose steroids on long-term all-cause mortality and cardiovascular death, the IVIG group appeared to experience fewer deaths than the PSM control group.

Study population and design

The present study aimed to evaluate the effects of IVIG and high-dose steroids, which prompted us to aim to exclude potentially confounding baseline characteristics. Aside from baseline characteristics, the usage and duration of MCS were considered the most important confounding factors. This is because MCS is a main therapy for severe cardiogenic shock in pediatric acute myocarditis, and is known to influence the rates of in-hospital mortality and long-term survival [18]. However, the duration of MCS was difficult to account for based on its relative rarity, which led us to exclude patients who received MCS (i.e., extracorporeal membrane oxygenation and intra-aortic balloon pumping). Previous studies regarding acute myocarditis in the pediatric population have also been limited by their small sample size and the emergent nature of acute myocarditis. Therefore, we used PSM to reduce any selection bias in this cohort study.

Endomyocardial biopsy and viral detection are usually recommended for acute myocarditis, although patients in this study rarely underwent cardiac biopsy. Despite endomyocardial biopsy being considered safe in the adult population [19], its rarity for diagnosing myocarditis in pediatric patients may be related to the high risk of myocardial injury that is associated with the lack of available facilities and clinical experience [20]. Furthermore, although many patients underwent testing to detect viral infection, which was typically performed within 3 days in clinical practice, we could not obtain the related laboratory data. Therefore, the biopsy and viral detection statuses were included in the PSM to eliminate their influences on clinical outcomes.

Moreover, the present study included only a small proportion of patients who received medication for heart failure. This is likely related to the high spontaneous recovery rate after discharge, drug intolerance in very young patients, and a lack of randomized controlled trials in the pediatric population. Nevertheless, the findings of our study reflect the real-world practice in Taiwan.

Outcomes related to high-dose steroid therapy

The pathology of myocarditis can be divided into three phases that involve the host’s innate immune response to virus-infected cells and the subsequent autoimmune reactions [21]. Because immune dysfunction may play a primary role in many cases of myocarditis, immunotherapy may shorten its course, lessen its severity, and improve long-term outcomes. In this context, prednisolone mimics natural steroids during the response to stress and help reduce the subsequent host inflammatory response, even though there are several well-known adverse events. Gagliardi et al. have reported that immunosuppression therapy improved left ventricular function and survival in 68–100% of children [22]. Burch et al. have also suggested that immunosuppression is safe in pediatric subjects with acute myocarditis, although the therapeutic effects were unclear [23]. Unfortunately, a recent systemic review and meta-analysis revealed that immunosuppressive treatment might help improve left ventricular systolic function and clinical symptoms, but did not significantly influence mortality and the incidence of heart transplantation in 3 studies [10, 11]. However, many studies were limited by their small sample size, lack of control groups, short follow-up duration, heterogeneous outcome definitions, and variability in the therapeutic regimens. The present study addressed the issues of small sample sizes and lack of comparable control groups, which revealed that use or non-use of high-dose steroid treatment did not significantly influence the rates of in-hospital mortality, subsequent heart failure hospitalization, or all-cause mortality.

Outcomes related to IVIG

Because IVIG has anti-inflammatory, immune-modulating, and anti-oxidative stress effects, it seems reasonable that it would be helpful during the initial phase of myocarditis in terms of improving left ventricle function [24, 25, 26, 31]. Other studies have demonstrated that IVIG could improve cardiovascular outcomes by decreasing the risk of cardiogenic shock, fatal arrhythmia, or complete heart block [27, 28, 29, 30]. However, Yu et al. [28] detected no significant difference in the mortality rates of groups that did and did not receive IVIG (2/32 vs 7/26; P = 0.072). Another recent multi-center study also revealed no significant survival benefit from IVIG treatment for pediatric patients with acute myocarditis [31]. However, these studies were also limited by their small sample sizes and the lack of control groups. The present study addressed those limitations using PSM in a nationally representative cohort, which revealed that IVIG did not significantly influence the rates of in-hospital mortality and post-discharge late heart failure hospitalization. Nevertheless, given the absence of cases with late mortality in the IVIG group, further large prospective studies are needed to evaluate its potential survival benefit.

Study limitations

This study has several limitations. First, the data were retrospectively retrieved from a large administrative database that depends on the coding accuracy of the participating hospitals, and the diagnoses are not as clearly validated as those in prospective registries or studies. However, medical payment directed from medical managements of individual diagnosis is strictly controlled by Taiwan National Health Insurance’s provision. Therefore, though we can’t determine whether the diagnosis was made according to the European Society of Cardiology (ESC) take force proposed criteria in our insurance database [32], we assumed that the wrong diagnosis from clear criteria to be less likely. In addition, pediatric subjects have fewer comorbidities than adult patients, and patients with complex pre-admission comorbidities were excluded to eliminate any related issues. Second, the NHIRD does not include detailed information regarding hemodynamic status, laboratory data (including cardiac troponin levels), clinical severity assessments, treatment, or response. Although high cardiac troponin levels are reportedly associated with poor cardiac function in acute phase, several other studies have indicated that troponin levels did not influence long-term clinical outcomes [33, 34, 35, 36]. Nevertheless, the PSM was adjusted for several variables that are reportedly related to outcomes (age distribution, anti-heart failure medication, and usage of inotropic agents) and severity (VT/VF, bradyarrhythmia, CPR use, and ICU stay). Third, we could not assess echocardiographic results or other images to predict prognosis, although a large study has demonstrated that those parameters (e.g., left ventricular ejection fraction, end-diastolic pressure, and end-diastolic dimension index) were not related to poor outcomes [37]. Finally, we did not have access to data regarding biopsy and viral testing results, which precluded any confirmation of the response to immunosuppressive therapy (e.g., development of giant myocarditis, eosinophilic myocarditis, or autoimmune related myocarditis). Thus, to address this issue, we excluded patients with autoimmune diseases before or after the index admission. Furthermore, the sensitivity of endocardial biopsy is limited under the Dallas criteria or for viral detection.

Conclusion

The lack of conclusive data has led to controversy regarding the efficacy of immunomodulatory therapy (e.g., IVIG or high-dose steroids) for pediatric myocarditis. This Taiwanese– retrospective cohort study provides real-world clinical evidence that high-dose steroid treatment or IVIG treatment have neutral effects on the rates of in-hospital complications and post-discharge outcomes among pediatric patients with acute myocarditis. These results may help guide the approach to using these treatments in clinical practice.

Notes

Acknowledgments

We thank Alfred Hsing-Fen Lin and Zoe Ya-Jhu Syu for the assistance with statistics.

Funding

This work was supported by the research grant from Chang Gung Memorial Hospital (CMRPG6E0171 and CORPG6D0161) and the funding organization did not have any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The data that support the findings of this study are available from National Health Insurance Research Database (NHIRD) in Taiwan but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of NHIRD.

Authors’ contributions

MSL, YHT, MYC, YSL were involved in the study concept and design. CMC, MHT, THC, JJC were involved in the field study and data acquisition. CMC, MHT, PCW, JJC were involved in the analysis and interpretation of the data. MSL, YHT were involved in the drafting of manuscript. MYC, YSL were involved in the critical revision of manuscript. All authors have read and approved the manuscript.

Ethics approval and consent to participate

This study was approved by the institutional review board ethical committee (Chang-Gung Memorial Hospital Ethics Committee No 103-6244B).

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Leonard EG. Viral myocarditis. Pediatr Infect Dis J. 2004;23(7):665–6.CrossRefGoogle Scholar
  2. 2.
    Webber SA, Boyle GJ, Jaffe R, Pickering RM, Beerman LB, Fricker FJ. Role of right ventricular endomyocardial biopsy in infants and children with suspected or possible myocarditis. Br Heart J. 1994;72(4):360–3.CrossRefGoogle Scholar
  3. 3.
    May LJ, Patton DJ, Fruitman DS. The evolving approach to pediatric myocarditis: a review of the current literature. Cardiol Young. 2011;21(3):241–51.  https://doi.org/10.1017/S1047951110001964 Epub 2011 Jan 28.CrossRefPubMedGoogle Scholar
  4. 4.
    Chan KY, Iwahara M, Benson LN, Wilson GJ, Freedom RM. Immunosuppressive therapy in the management of acute myocarditis in children: a clinical trial. J Am Coll Cardiol. 1991;17(2):458–60.CrossRefGoogle Scholar
  5. 5.
    Kleinert S, Weintraub RG, Wilkinson JL, Chow CW. Myocarditis in children with dilated cardiomyopathy: incidence and outcome after dual therapy immunosuppression. J Heart Lung Transplant. 1997;16(12):1248–54.PubMedGoogle Scholar
  6. 6.
    Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME. Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med. 1995;333(5):269–75.CrossRefGoogle Scholar
  7. 7.
    Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati M, Stolf N, Ebaid M, Pileggi F. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol. 1995;16(2):61–8.CrossRefGoogle Scholar
  8. 8.
    Aziz KU, Patel N, Sadullah T, Tasneem H, Thawerani H, Talpur S. Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young. 2010;20(5):509–15.  https://doi.org/10.1017/S1047951110000594 Epub 2010 Jun 28.CrossRefPubMedGoogle Scholar
  9. 9.
    Hia CP, Yip WC, Tai BC, Quek SC. Immunosuppressive therapy in acute myocarditis: an 18 year systematic review. Arch Dis Child. 2004;89(6):580–4.CrossRefGoogle Scholar
  10. 10.
    Lu C, Qin F, Yan Y, Liu T, Li J, Chen H. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown). 2016;17(8):631–7.  https://doi.org/10.2459/JCM.0000000000000134.CrossRefGoogle Scholar
  11. 11.
    Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2013;10:CD004471.Google Scholar
  12. 12.
    Foerster SR, Canter CE, Cinar A, Sleeper LA, Webber SA, Pahl E, Kantor PF, Alvarez JA, Colan SD, Jefferies JL, Lamour JM, Margossian R, Messere JE, Rusconi PG, Shaddy RE, Towbin JA, Wilkinson JD, Lipshultz SE. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood. Circ Heart Fail. 2010;3(6):689–97.  https://doi.org/10.1161/CIRCHEARTFAILURE.109.902833 Epub 2010 Sep 10.CrossRefPubMedGoogle Scholar
  13. 13.
    Ghelani SJ, Spaeder MC, Pastor W, Spurney CF, Klugman D. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):622–7 Epub 2012 Jul 24.CrossRefGoogle Scholar
  14. 14.
    Klugman D, Berger JT, Sable CA, He J, Khandelwal SG, Slonim AD. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol. 2010;31(2):222–8.  https://doi.org/10.1007/s00246-009-9589-9.CrossRefPubMedGoogle Scholar
  15. 15.
    Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236–42.  https://doi.org/10.1002/pds.2087 Epub 2010 Dec 29.CrossRefPubMedGoogle Scholar
  16. 16.
    Isogai T, Yasunaga H, Matsui H, Tanaka H, Horiguchi H, Fushimi K. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail. 2015;21(5):391–7.  https://doi.org/10.1016/j.cardfail.2015.01.004 Epub 2015 Jan 30.CrossRefPubMedGoogle Scholar
  17. 17.
    Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092–7.CrossRefGoogle Scholar
  18. 18.
    Rajagopal SK, Almond CS, Laussen PC, Rycus PT, Wypij D, Thiagarajan RR. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the extracorporeal life support organization registry. Crit Care Med. 2010;38(2):382–7.  https://doi.org/10.1097/CCM.0b013e3181bc8293.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sławek S, Araszkiewicz A, Gaczkowska A, Koszarska J, Celiński D, Grygier M, Lesiak M, Grajek S. Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool. BMC Cardiovasc Disord. 2016;16(1):222.CrossRefGoogle Scholar
  20. 20.
    Pophal SG, Sigfusson G, Booth KL, Bacanu SA, Webber SA, Ettedgui JA, Neches WH, Park SC. Complications of endomyocardial biopsy in children. J Am Coll Cardiol. 1999;34(7):2105–10.CrossRefGoogle Scholar
  21. 21.
    Kawai C. From myocarditis to cardiomyopathy mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99(8):1091–100.CrossRefGoogle Scholar
  22. 22.
    Gagliardi MG, Bevilacqua M, Bassano C, Leonardi B, Boldrini R, Camassei FD, Fierabracci A, Ugazio AG, Bottazzo GF. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart. 2004;90(10):1167–71.CrossRefGoogle Scholar
  23. 23.
    Burch M. Immune suppressive treatment in pediatric myocarditis: still awaiting the evidence. Heart. 2004;90(10):1103–4.CrossRefGoogle Scholar
  24. 24.
    McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103(18):2254–9.CrossRefGoogle Scholar
  25. 25.
    Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89(1):252–7.CrossRefGoogle Scholar
  26. 26.
    Robinson J, Hartling L, Vandermeer B, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev 2015;(5):CD004370.  https://doi.org/10.1002/14651858.CD004370.pub3.
  27. 27.
    Prasad AN, Chaudhary S. Intravenous immunoglobulin in children with acute myocarditis and/or early dilated cardiomyopathy. Indian Pediatr. 2014;51(7):583–4.CrossRefGoogle Scholar
  28. 28.
    Yu DQ, Wang Y, Ma GZ, Xu RH, Cai ZX, Ni CM, Chen P, Zhu ZD. Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: a retrospective study. Exp Ther Med. 2014;7(1):97–102 Epub 2013 Oct 29.CrossRefGoogle Scholar
  29. 29.
    Kim HS, Sohn S, Park JY, Seo JW. Fulminant myocarditis successfully treated with high dose immunoglobulin. Int J Cardiol. 2004;96(3):485–6.CrossRefGoogle Scholar
  30. 30.
    Tsai YG, Ou TY, Wang CC, Tsai MC, Yuh YS, Hwang B. Intravenous gamma-globulin therapy in myocarditis complicated with complete heart block: report of one case. Acta Paediatr Taiwan. 2001;42(5):311–3.PubMedGoogle Scholar
  31. 31.
    Atiq M, Hoda M, Aslam N. Effect of intravenous gamma globulin on short- and mid-term clinical outcome in acute viral myocarditis in children. World Journal of Cardiovascular Diseases. 2014;4:39–44.CrossRefGoogle Scholar
  32. 32.
    Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48.CrossRefGoogle Scholar
  33. 33.
    Ammann P, Naegeli B, Schuiki E, et al. Long-term outcome of acute myocarditis is independent of cardiac enzyme release. Int J Cardiol. 2003;89(2–3):217–22.CrossRefGoogle Scholar
  34. 34.
    Kobayashi D, Aggarwal S, Kheiwa A, Shah N. Myopericarditis in children: elevated troponin I level does not predict outcome. Pediatr Cardiol. 2012;33(7):1040–5.CrossRefGoogle Scholar
  35. 35.
    Massin M, Crochelet AS, Jacquemart C. Acute myocarditis with very high troponin but no ventricular dysfunction. Clin Pediatr (Phila). 2017;56(6):582–3.CrossRefGoogle Scholar
  36. 36.
    Butto A, Rossano JW, Nandi D, et al. Elevated troponin in the first 72 h of hospitalization for pediatric viral myocarditis is associated with ECMO: an analysis of the PHIS+ database. Pediatr Cardiol. 2018;39(6):1139–43.CrossRefGoogle Scholar
  37. 37.
    Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, Lindinger A, Böhm M. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639–48.  https://doi.org/10.1161/CIRCULATIONAHA.108.769489. Epub 2008 Jul 21.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s). 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Ming-Shyan Lin
    • 1
  • Yu-Hsiang Tseng
    • 1
  • Mei-Yen Chen
    • 2
    • 3
  • Chang-Min Chung
    • 1
  • Ming-Horng Tsai
    • 4
  • Po-Chang Wang
    • 1
  • Jung-Jung Chang
    • 1
  • Tien-Hsing Chen
    • 5
  • Yu-Sheng Lin
    • 1
    Email author return OK on get
  1. 1.Department of CardiologyChiayi Chang Gung Memorial HospitalChai Yi HsienTaiwan
  2. 2.Department of NursingChang Gung University of Science and TechnologyTaoyuanTaiwan
  3. 3.Department of NursingChang Gung UniversityTaoyuanTaiwan
  4. 4.Department of PediatricsChang Gung Memorial HospitalYunlin,Taiwan
  5. 5.Department of CardiologyChang Gung Memorial HospitalKeelungTaiwan

Personalised recommendations